NEW YORK (GenomeWeb News) – LED Medical Diagnostics this week announced an agreement to form a collaboration to develop and commercialize a progression-risk assessment test for oral cancer.

The agreement is with BC Cancer Agency to form a relationship with Genome British Columbia. The test, LED said, is based on loss of heterozygosity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.